Piper Jaffray downgrades Isis Pharmaceuticals (Nasdaq: ISIS) from Overweight to Neutral and decreases the price target from $13 to $10 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE